How to buy Personalis stock (PSNL)

Personalis is a diagnostics & research business based in the US. Personalis shares (PSNL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.75 – an increase of 50.52% over the previous week. Personalis employs 223 staff and has a trailing 12-month revenue of around $87.5 million.

Our top picks for where to buy Personalis stock

Buy Personalis stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Personalis stock price (NASDAQ: PSNL)

Use our graph to track the performance of PSNL stocks over time.

Personalis shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$5.75
52-week range	$1.12 - $7.20
50-day moving average more info button	$4.40
200-day moving average more info button	$3.12
Wall St. target price	$7.02
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.73

Is it a good time to buy Personalis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Personalis price performance over time

Historical closes compared with the close of $5.26 from 2024-12-19

1 week (2024-12-13)	37.70%
1 month (2024-11-21)	55.62%
3 months (2024-09-20)	-8.36%
6 months (2024-06-21)	331.15%

1 year (2023-12-21)	248.34%
2 years (2022-12-21)	190.61%
3 years (2021-12-21)	14.67
5 years (2019-12-20)	9.7

Personalis financials

Revenue TTM	$87.5 million
Gross profit TTM	$13.4 million
Return on assets TTM	-18.78%
Return on equity TTM	-57.52%
Profit margin	-104.52%
Book value	$2.36
Market Capitalization more info button	$251.5 million

TTM: trailing 12 months

Personalis share dividends

We're not expecting Personalis to pay a dividend over the next 12 months.

Personalis share price volatility

Over the last 12 months, Personalis's shares have ranged in value from as little as $1.12 up to $7.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Personalis's is 1.945. This would suggest that Personalis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Personalis overview

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients.

Frequently asked questions

What percentage of Personalis is owned by insiders or institutions?
Currently 19.297% of Personalis shares are held by insiders and 53.171% by institutions. How many people work for Personalis?
Latest data suggests 223 work at Personalis. When does the fiscal year end for Personalis?
Personalis's fiscal year ends in December. Where is Personalis based?
Personalis's address is: 6600 Dumbarton Circle, Fremont, CA, United States, 94555 What is Personalis's ISIN number?
Personalis's international securities identification number is: US71535D1063 What is Personalis's CUSIP number?
Personalis's Committee on Uniform Securities Identification Procedures number is: 71535D106